Anthony Olszanski is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 439 publications with 9,761 citations (h-index 44); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Cottman Ave
Medical Staff Office
Philadelphia, PA 191112434
Telephone
215-728-6900Registry record last updated 9 Apr 2018.
Clinical trials
- Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Sponsor: Fox Chase Cancer Center
- A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Sponsor: Intensity Therapeutics, Inc.
- A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Sponsor: Fox Chase Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Daiichi Sankyo Inc.Program year20252 payments
- Regeneron Healthcare Solutions, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2021–2024 per NIH RePORTER. The latest:
- A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
Research Inst of Fox Chase Can Ctr
FY2024$208,738R21CA277402 - A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
Research Inst of Fox Chase Can Ctr
FY2023$263,670R21CA277402 - A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib
Wistar Institute
FY2022$316,269R01CA225913
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
Cancer Chemotherapy and Pharmacology
2023 - Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Martin Edelman, MD
Fox Chase Cancer Center
Shazia Nakhoda, MD
Fox Chase Cancer Center
Hossein Borghaei, MD
Fox Chase Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”